丝裂霉素C诱导的肺静脉闭塞性疾病:特征与长期结局
该研究基于法国肺动脉高压登记系统,纳入2011年6月至2018年12月间17例丝裂霉素C诱导的肺静脉闭塞性疾病患者。诊断时患者临床和功能损害严重,NYHA心功能III或IV级12例,6分钟步行距离220(0-465)m,右心导管证实重度毛细血管前肺动脉高压,平均肺动脉压38(30-52)mm Hg,心指数2.2(1.5-4)L/(min×m²),肺血管阻力8.3(5.1-14.5)Wood单位,一氧化碳弥散量降至理论值的31%(20%-51%)并伴严重低氧血症。所有患者停用丝裂霉素C,14例接受PAH靶向治疗,再评估时NYHA分级(P=.10)、6分钟步行距离(P=.09)和肺血管阻力(-4.7 Wood单位;P=.052)有轻度但无统计学意义的改善;3例出现肺水肿需停用或减量PAH治疗。中位总生存期20个月,6、12、24个月生存率分别为76%、58%、18%。
要点
- 丝裂霉素C暴露后出现肺动脉高压者应警惕肺静脉闭塞性疾病,本研究17例诊断时平均肺动脉压38(30-52)mm Hg、肺血管阻力8.3(5.1-14.5)Wood单位。
- 诊断时一氧化碳弥散量降至理论值31%(20%-51%)并伴严重低氧血症,提示该病气体交换损害突出。
- 停用丝裂霉素C并给予PAH靶向治疗后,NYHA分级(P=.10)、6分钟步行距离(P=.09)和肺血管阻力(-4.7 Wood单位;P=.052)仅轻度改善且未达统计学显著。
- 14例接受PAH靶向治疗的患者中3例出现肺水肿,需停用或减量PAH治疗。
- 中位总生存期20个月,6、12、24个月生存率分别为76%、58%、18%,预后差。
适用人群与场景
- 法国肺动脉高压登记系统中,2011年6月至2018年12月间诊断的、有丝裂霉素C暴露史的肺静脉闭塞性疾病患者,共17例。
处置流程与药物剂量
- 所有患者停用丝裂霉素C;14例接受特异性肺动脉高压(PAH)靶向治疗。
- PAH靶向治疗再评估(中位延迟4.8个月)时,3例出现肺水肿,需停用或减量PAH治疗。
红旗征与不能漏的情况
- PAH靶向治疗期间出现肺水肿,需停用或减量PAH治疗。
研究设计与关键结果
- 研究类型为基于法国肺动脉高压登记系统的病例系列,纳入2011年6月至2018年12月17例丝裂霉素C诱导的肺静脉闭塞性疾病患者。
- 诊断时12例NYHA心功能III或IV级,6分钟步行距离220(0-465)m;右心导管示平均肺动脉压38(30-52)mm Hg、心指数2.2(1.5-4)L/(min×m²)、肺血管阻力8.3(5.1-14.5)Wood单位;一氧化碳弥散量为理论值的31%(20%-51%)并伴严重低氧血症。
- 所有患者停用丝裂霉素C,14例接受PAH靶向治疗;再评估(中位延迟4.8个月)时NYHA分级(P=.10)、6分钟步行距离(P=.09)和肺血管阻力(-4.7 Wood单位;P=.052)有轻度但无统计学意义的改善。
- 3例接受PAH靶向治疗的患者出现肺水肿,需停用或减量PAH治疗。
- 中位总生存期20个月,6、12、24个月生存率分别为76%、58%、18%。
证据类型、等级与局限
- 证据类型:基于法国肺动脉高压登记系统的病例系列(17例)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对有丝裂霉素C暴露史的肺动脉高压患者,应考虑肺静脉闭塞性疾病可能,本研究显示该病诊断时血流动力学损害重、预后差。
- PAH靶向治疗期间需警惕肺水肿,本研究中3例因此需停用或减量PAH治疗。
- 作者认为,丝裂霉素C治疗后发生的肺静脉闭塞性疾病是一种罕见但危及生命的并发症,尽管停用丝裂霉素C并给予PAH特异性治疗,预后仍差。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Pulmonary venoocclusive disease (PVOD) is an uncommon form of pulmonary hypertension (PH) predominantly characterized by pulmonary vein and capillary involvement. An association between chemotherapy, in particular mitomycin C (MMC), and PVOD has been reported.
RESEARCH QUESTION: What are the characteristics of MMC-induced PVOD, and what is the prognosis for patients with MMC-induced PVOD?
STUDY DESIGN AND METHODS: We report the clinical, functional, radiologic, and hemodynamic characteristics at diagnosis and outcomes of patients with PVOD from the French PH Registry after exposure to MMC. The results are expressed as the median (minimum-maximum).
RESULTS: From June 2011 to December 2018, 17 incident cases of MMC-induced PVOD were identified. At diagnosis, these patients had severe clinical and functional impairment, with 12 patients having a New York Heart Association (NYHA) functional class of III or IV and a 6-min walk distance of 220 (0-465) m. Right heart catheterization confirmed severe precapillary PH with a mean pulmonary artery pressure of 38 (30-52) mm Hg, a cardiac index of 2.2 (1.5-4) L/(min × m2), and pulmonary vascular resistance of 8.3 (5.1-14.5) Wood units. The diffusing capacity of the lungs for carbon monoxide was markedly decreased at 31% (20%-51%) of the theoretical values associated with severe hypoxemia. MMC was withdrawn for all patients, and 14 patients received specific pulmonary arterial hypertension (PAH) therapies. Among these patients, mild but statistically insignificant improvements were observed in NYHA functional class (P = .10), 6-min walk distance (P = .09), and pulmonary vascular resistance (-4.7 Wood units; P = .052) at reassessment (median delay of 4.8 months). Three patients experienced pulmonary edema requiring the cessation or reduction of PAH treatment. The median overall survival was 20 months, and the 6-, 12-, and 24-month survival rates were 76%, 58%, and 18%, respectively.
INTERPRETATION: PVOD after MMC treatment is a rare but life-threatening complication associated with a poor prognosis despite MMC withdrawal and PAH-specific therapy.
参考来源
- Certain MC, Chaumais MC, Jaïs X, et al. Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C. Chest. 2020. PMID: 32979348. doi:10.1016/j.chest.2020.09.238
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。